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T-cell transmigration, and this effect was 
inhibited by galardin, suggesting MMP 
involvement.
The same authors recently published 
a study in which they demonstrated that 
IL-13, another mediator derived from 
mast cells and T helper 2 cells, can also 
induce MMP-9 in keratinocytes, pro-
mote collagen type IV degradation, and 
increase T-cell transmigration through 
Matrigel. However, neither additive nor 
synergistic MMP-9 expression could be 
detected when IL-13 acted together with 
TGF-β or TNF-α (Purwar et al., 2008).
concluding remarks
The present study provides interest-
ing insights into the role of histamine 
in skin inflammation and epidermal 
pathology. In fact, a variety of mast cell 
mediators, including histamine, IL-13, 
TNF-α, and TGF-β, can evidently stimu-
late keratinocytes for MMP-9 expression 
(Figure 1). Furthermore, different com-
binations of these mediators can even 
lead to enhanced proteinase expres-
sion. Nevertheless, it must be clarified 
whether this histamine-induced MMP-9 
expression, and possibly also induction 
of other MMPs, together with subsequent 
basement membrane degradation and 
T-cell transmigration to the epidermis, 
actually take place in vivo in pathologic 
processes, such as psoriasis, eczema, or 
skin blistering, with resultant epidermal 
inflammation. It is noteworthy that his-
tamine can also simultaneously induce 
numerous other molecules in keratino-
cytes and that these molecules can also 
impact immunopathogenesis. Because 
histamine can act together with TNF-α, 
IFN-γ, and TGF-β, leading to an enhanced 
biological effect, it is tempting to specu-
late that antihistamines might enhance 
the therapeutic effects of TNF-α-blocking 
drugs (Cordiali-Fei et al., 2006).
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Tumor Evasion May Occur via 
Expression of Regulatory Molecules: 
A Case for CTLA-4 in Melanoma
Jeffrey S. Weber1
Emerging data that show immune-regulating molecules may be ectopically 
expressed on human tumors suggest that novel mechanisms may induce tumor-
related immune suppression, and support the use of antibodies and small 
molecules to target those immune-suppressive moities.
Journal of Investigative Dermatology (2008), 128, 2750–2752. doi:10.1038/jid.2008.341
In the words of Oscar Wilde, “To expect 
the unexpected shows a thoroughly 
modern intellect.” In this issue of the 
Journal of Investigative Dermatology, 
Shah et al. (2008) describe the upregu-
lation of a variety of genes induced in 
melanoma cell lines by Wnt-β/catenin 
signaling. Surprisingly and unexpect-
edly, cytotoxic T-lymphocyte antigen-4 
(CTLA-4), an immune regulatory mol-
ecule, emerged as the gene product 
most highly increased in the authors’ 
transcriptional profiling and expres-
sion array analysis of melanoma cell 
lines treated with recombinant Wnt 
3a. CTLA-4 is a molecule expressed on 
T cells that delivers a signal decreas-
ing T-cell activation by the recruitment 
of tyrosine and serine/threonine phos-
phatases (Walunas et al., 1994; Kummel 
and Allison, 1996). CTLA-4 is clearly 
inhibitory for T-cell activation because 
lymphoproli ferative/autoimmune 
events are observed in CTLA-4–/– mice. 
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of CTLA-4 seemed unchanged, sug-
gesting that intracellular, nonfunctional 
CTLA-4 was actually modulated by 
Wnt-a signaling. The data are admit-
tedly derived from only two cell lines 
and may not be representative of all 
melanomas; in addition, as opposed to 
work performed previously, no func-
tional studies were undertaken to dem-
onstrate that physiologic consequences 
might arise from Wnt-induced CTLA-4 
expression by melanoma cell lines, so 
some caution in interpreting the results 
of this work is indicated. Nonetheless, 
the experiments described in this work 
are of importance and require follow-
up, because even low levels of extra-
cellular CTLA-4 in the presence of high 
levels of intracellular material can be 
functional (Contardi et al., 2005).
What is the implication of this work 
and the work of others cited above? 
First, the results indicate that tumor 
cell expression of immune regulatory 
molecules might be more widespread 
than previously thought and may be yet 
another important immune-suppressive 
mechanism in humans. Alternatively, 
we may need to expand our concept 
of CTLA-4 as an immune-modulating 
molecule and ask whether it might 
have other functions in the regulation 
of nonlymphoid cells under the control 
of the Wnt family. Recent clinical tri-
als with two different CTLA-4 abrogat-
ing antibodies have indicated that they 
have clinical activity against melanoma 
and other malignancies. If the results 
of ongoing large phase III trials of ipili-
mumab, a human IgG1 anti-CTLA-4 
antibody from Bristol-Myers Squibb, are 
positive, then a more extensive analysis 
of tumors from patients who received 
the antibody is in order to assess wheth-
er clinical benefit might correlate with 
tumor-related CTLA-4 expression.
Could other molecules that are 
traditionally thought of as having 
immunity-regulating activity also 
other members of the tumor necro-
sis factor receptor superfamily, is also 
found at low levels on colon and other 
cancer cells and can exert a functional 
effect when cells expressing 4-1BB are 
treated with its soluble ligand (Salih et 
al., 2000). These data suggest a theme 
by which tumors can evolve to an 
immune evasion phenotype and inhib-
it adaptive and innate immunity by 
exploiting naturally expressed immune 
regulatory molecules, and they suggest 
strategies to overcome this phenom-
enon as well as possible new predic-
tive markers for the success or failure 
of current immuno regulatory antibody 
treatments.
Prior studies have demonstrated that 
CTLA-4 is expressed not only on acti-
vated T cells but also on cells of the 
monocytic lineage, cultured muscle 
cells, and placental fibroblasts. CTLA-4 
has previously been demonstrated on 
melanoma cell lines; a variety of other 
human tumor cell lines such as osteo-
sarcoma, neuroblastoma, and infiltrat-
ing breast cancer lines; and lymphoid 
and myeloid leukemia cells (Contardi et 
al., 2005). CTLA-4 was found on sarco-
ma and breast cancer tissue, as demon-
strated by immunohistochemical stain-
ing. Interestingly, when soluble B7.1 or 
B7.2 was used to treat the tumor lines 
expressing CTLA-4 in the above work, 
apoptosis indicated by increases in 
cleaved caspases 3 and 8 was observed, 
suggesting that the tumor cell–derived 
CTLA-4 was functional.
The targets of Wnt signaling include 
genes of the melanocytic pathway 
such as MITF, as well as lymphoid-
related genes. Signaling through Wnt 
clearly plays a role in melanocytic 
development and may be a marker of 
aggressive behavior in melanoma via 
an interaction with the protein kinase 
C pathway (Weeraratna et al., 2002). In 
their analysis in the current work, Shah 
et al. (2008) demonstrate that CTLA-4 
was present not only on melanoma cell 
lines but also on human epidermal mel-
anocytes and melanoma tumors using 
flow cytometry staining. The expres-
sion on the melanoma cell lines and 
the melanocytes was clearly increased 
by Wnt-3a and represented full-
length (not truncated) RNA transcripts. 
However, the actual surface expression 
In patients, the abrogation of CTLA-4 
activity with human monoclonal anti-
bodies leads not only to autoimmune 
side effects but also to sustained tumor 
regression or stable disease in selected 
patients with advanced melanoma. The 
unexpected presence of CTLA-4 on 
tumor cell lines and in the analysis by 
Shah et al. of early-stage and metastatic 
melanoma tumors is consistent with 
data from at least one prior publication 
on this topic, but it nicely expands the 
emerging story of how expression of 
“ectopic” immune regulatory molecules 
by tumor cells may alter the balance 
between immune stimulation and inhi-
bition. CTLA-4 expression by tumors 
may represent yet another mechanism 
by which tumors actively suppress, 
evade, and avoid T-cell immunity and 
exhibit immune “escape.”
Immune regulatory molecules have 
previously been demonstrated to be 
expressed on a variety of human and 
murine tumors. B7-1, or CD80, is a 
molecule commonly found on acti-
vated antigen-presenting cells such as 
dendritic cells, B cells, and macrophag-
es and has been found on murine 
colon tumors at a low level, resulting 
in immune downmodulation (Tirapu 
et al., 2006). A dichotomous relation-
ship of B7-1 likely exists, because high 
levels of CD80 or CD86 on tumor cells 
driven by gene engineering increase, 
rather than decrease, their immuno-
genicity. CD80 and the similar co-
stimulatory molecule CD86 have also 
been reported at low levels on a broad 
variety of tumor cell lines by flow 
cytometry analysis and reverse tran-
scriptase PCR (Contardi et al., 2005). 
Programmed death ligand-1 (PD-L1, or 
B7-H1) is another molecule expressed 
on activated human antigen-presenting 
cells and is commonly found on mela-
nomas, as well as in colon, breast, and 
lung cancers. PD-L1 acts as a further 
“brake” on immune activation, simi-
larly to CTLA-4. High levels of PD-L1 
bind to the PD-1 receptor on T cells 
and limit T-cell proliferation, function, 
and activation via the T-cell receptor 
(Dong et al., 2002). Levels of PD-L1 on 
tumors correlate with a poor outcome 
in ovarian and other human cancers 
(Hamanishi et al., 2007). Finally, the 
co-stimulatory molecule 4-1BB, like 
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function in a nonimmune milieu, like 
PD-L1, a suppressive influence, and 
4-1BB, an immunity-stimulating recep-
tor? The ability to quantitate molecules 
such as CTLA-4 on and within tumors 
by immunohistochemical staining or 
their detection as soluble molecules in 
the serum of cancer patients merits their 
exploration as prognostic markers, and 
even predictive markers, for therapy 
using antibodies to CTLA-4 and other 
immunity regulatory molecules in devel-
opment. Finally, the clearest therapeutic 
implications of the current work are the 
indication of a new mechanism for the 
utility of CTLA-4-abrogating antibod-
ies and the suggestion that using a non-
toxic pretreatment to upregulate those 
molecules on melanomas might pro-
vide a synergistic mechanism by which 
the utility of the antibodies may be aug-
mented. New small-molecule synergists 
of Wnt signaling are becoming available, 
and they warrant testing in a strategy to 
add to the antitumor activity of CTLA-4 
abrogation (Zhang et al., 2007). Shah 
et al. (2008) have demonstrated a thor-
oughly modern intellect by documenting 
the unexpected expression of CTLA-4 on 
melanoma and its upregulation by Wnt 
signaling.
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